Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population could be eligible to take them, and patients have to stay on the drugs to keep the weight off.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound. Her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide. Still, she continued to feel too nauseous, so she decided by herself to start skipping every other dose.

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.

Consumer Reports looked at how weight loss drugs and possible side effects in older adults. The Lavi: A jet built to dominate the skies but grounded by politics. Designed to ensure air supremacy, Israel’s cutting-edge fighter combined incredible agility,